Q-omics provides the consensus-scored RPL10P7 profile across patient tissues and cancer cell-line models. RPL10P7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SARC. Among the 18 cancer types available for tumor–normal comparison, RPL10P7 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, RPL10P7 RNA expression shows 8,937 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SARC, BLCA, and TGCT as cancer lineages where RPL10P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL10P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL10P7 survival associations across molecular data types. RPL10P7 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL10P7 RNA expression–survival associations across cancer types. High RPL10P7 expression shows unfavorable associations in STAD, but favorable associations in SARC, CESC, READ, LUSC and UVM. The SARC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SARC as the clearest survival context for RPL10P7 RNA expression.
This table summarizes RPL10P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL10P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL10P7 shows lower tumor expression in BLCA, LUSC, UCEC, BRCA, KICH and THCA. The BLCA box plot shows higher RPL10P7 RNA expression in normal versus tumor tissue (log2 FC = −1.216, t-test p < 0.001).
This table shows molecular features associated with RPL10P7 in patient tissues and cancer cell lines. In patient samples, RPL10P7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
